Navigation Links
Epitomics Releases New Antibodies Developed With the National Cancer Institute's Center for Cancer Research
Date:7/26/2011

BURLINGAME, Calif., July 26, 2011 /PRNewswire/ -- Epitomics, Inc., a biotechnology company commercializing the next generation of antibodies based on its groundbreaking Rabbit Monoclonal (RabMAb®) technology, today announced the Company has now launched 23 novel cancer-related antibodies that were developed through a partnership with the National Cancer Institute's Center for Cancer Research. The goal of this partnership is to develop novel, high quality reagents for cancer research and make them available to the scientific community.

"We are very excited to see the progress we have made in developing several key antibodies with NCI investigators and look forward to continuing working with them to develop high quality rabbit monoclonal antibodies," said Dr. Guo-Liang Yu, CEO, Epitomics, Inc.

All of the antibodies made under the collaboration are available for purchase in the USA directly through Epitomics and around the world through Epitomics international distributors. It is anticipated that another 20 antibodies will be developed through this partnership and released by Epitomics over the next 2 years.

Visit http://www.epitomics.com/products/nci to view the current list of antibodies released.

About Epitomics

Epitomics, Inc. is a biotechnology company dedicated to developing breakthrough monoclonal antibody technology for research and diagnostic applications. The Company's core technology is its unique and proprietary RabMAb(R) (Rabbit Monoclonal Antibody) technology which produces antibodies with superior binding affinity and bioactivity in a wide variety of biological assays. Epitomics has also developed a proprietary method for humanizing RabMAbs called Mutation Lineage Guided (MLG) humanization. Epitomics, Inc. is headquartered in Burlingame, California, and operates a wholly owned subsidiary in Hangzhou, the People's Republic of China. For more information about Epitomics, please visit www.epitomics.com.


'/>"/>
SOURCE Epitomics, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. Epitomics Signs Antibody Development Agreement With the National Cancer Institute
2. Berkery Noyes Releases First Half 2011 M&A Report for the Pharma and Healthcare Information and Technology Industry
3. Latest Releases of Elektas XiO Planning and Focal Contouring Systems Designed to Increase Efficiency in Planning Therapy for Patients with Cancer
4. Aethlon Medical Releases Shareholder Letter
5. Glycotex, Inc. Releases Final Phase II Clinical Trials Results in the Clinicaltrials.gov Database and Announces the Results of the Mechanism of Action Study for its Product Candidate GLYC-101
6. Ampio Pharmaceuticals, Inc. Releases Results From Phase III Clinical Trial of Zertane™ for the Treatment of Premature Ejaculation (PE), the Most Prevalent Form of Male Sexual Dysfunction
7. BGI Releases a Complete De Novo E. Coli O104 Genome Assembly and is Making Its Detection Kit Protocols and Synthesized Primers Freely Available to Worldwide Disease Control and Research Agencies
8. RF Technologies® Releases Code Alert® Quick Response® Wireless Call Solutions
9. Neuro Kinetics Releases Updated Version of Neuro-Otologic Control and Analysis Software
10. SCAI Releases Position Statement on Public Reporting and Risk Adjustment In Cardiovascular Quality Improvement Programs
11. SCAI Releases First Report on Transradial Access for Angioplasty and Stenting
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/23/2020)... ... June 23, 2020 , ... Today ... one of the first online COVID-19 trainings for health workers and others on ... free training entitled COVID-19 Training for Health Workers: Preparedness and Response ...
(Date:6/23/2020)... ... June 23, 2020 , ... ... "Company"), a leading provider of center-based, Applied Behavioral Analysis ("ABA") therapy, today ... ABA provider in the greater-Indianapolis market. This acquisition will make Lighthouse Autism ...
(Date:6/23/2020)... ... June 23, 2020 , ... Award-winning digital product design ... with over 60 million users, to build a COVID-19 map . The goal ... to date clarity through easy-to-understand data and visuals on the current COVID-19 situation both ...
Breaking Medicine Technology:
(Date:7/2/2020)... ... 2020 , ... Allegheny Health Network (AHN) today announced that John S. Lee, ... immediately. Dr. Lee succeeds Robert White, MD, who announced his plans for retirement ... year to help support a seamless transition. , Dr. Lee joins AHN from Edward-Elmhurst ...
(Date:7/1/2020)... ... July 01, 2020 , ... ... the clinical development of psychedelics and analogues, announces its core executive team. The ... natural product drug discovery, novel formulations, and as distinguished researchers within the cannabis ...
(Date:6/28/2020)... ... , ... Medisend College of Biomedical Engineering Technology, a Dallas-based ... prepares graduates for professional careers as field service engineers and biomedical equipment technicians, ... Ms. Williams currently serves as Associate Vice Chancellor of Workforce and Community Initiatives ...
(Date:6/28/2020)... , ... June 27, 2020 , ... The secret of ... of hundreds of rolls of toilet paper. Yet, it was the first product to ... sensible in theory. The more you have stockpiled, the less need to venture out, ...
(Date:6/25/2020)... ... , ... Denials Management, Inc. has just published The Health Insurance Appeals Guide ... denials of mental health and substance use disorder (MH/SUD) treatment services. It was written ... explain the steps in the appeals process. Complimentary copies of the Guide can ...
Breaking Medicine News(10 mins):